L&K Biomed Posts KRW 9.5 Billion in Q1 Sales... Turns Operating and Net Profit Positive

L&K Biomed, a company specializing in spinal implants, achieved a turnaround in both operating profit and net profit in the first quarter of this year, alongside sales growth. The improvement in performance was driven by growth in the Southeast Asian market and expanded sales of height-expandable cage products.

On May 15, L&K Biomed announced in a consolidated disclosure that its sales for the first quarter reached 9.5 billion won, with operating profit at 100 million won and net profit at 8 billion won.

Sales increased by 7% compared to 8.9 billion won in the same period last year. Both operating profit and net profit turned positive.

The company explained that stable sales growth in Southeast Asian markets, including Vietnam and Thailand, along with increased sales of height-expandable cage products, had a positive impact on improved performance.

Although selling and administrative expenses such as personnel costs rose somewhat due to proactive hiring for new product development and the expansion of the global supply chain, operating profit improved as a result of increased sales and favorable exchange rates. In addition, net profit saw a significant increase due to the recognition of derivative disposal gains during the repayment process of the 10th convertible bonds.

L&K Biomed is accelerating the expansion of its product portfolio, including the recently FDA-approved AccelFix-MIS (Dual thread type) spinal screw fixation system and the Castleloc-P Anterior Cervical Plate System. In particular, the company is strengthening its lineup of new products such as height-expandable cages for cervical applications, aiming to enhance competitiveness in the U.S. market.

The company anticipates that strengthening its cervical product lineup, which requires advanced technological capabilities, will have a positive impact on its competitiveness and performance growth in the U.S. market going forward.

A representative from L&K Biomed stated, "In the first half of the year, we are focusing on maintaining stable sales and profitability while laying the foundation for new product launches and the expansion of our global supply chain. In the second half, we plan to strengthen our sales and distribution network in the U.S. market to expand supply of new products such as the height-expandable cage for cervical applications."

The representative added, "We will strive to sustain stable performance growth by expanding our new product lineup and strengthening our global market response capabilities."

L&K Biomed is expected to accelerate performance growth in the second half of the year, based on its strategies to expand new products and strengthen its global distribution network.

This content was produced with the assistance of AI translation services.